NaseemaGangatMD

PubMed

• Methodological challenges in the development of endpoints for myelofibrosis clinical trials.
  Giovanni Barosi, Natasha Szuber, Alessandro Rambaldi, Nicolaus Kröger, Nico Gagelmann, Robert Peter Gale, Ayalew Tefferi, Naseema Gangat, Olatoyosi Odenike, Moshe Talp...> ;The Lancet. Haematology. 2024 Apr 8
• Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
  Naseema Gangat, Ayalew Tefferi> ;American Journal of Hematology. 2024 Apr 1
• 3 citations
  CALR mutation burden in essential thrombocythemia and disease outcome.
  Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Ale...> ;Blood. 2024 Mar 28
• Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
  Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, Wi...> ;Haematologica. 2024 Mar 28
• Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.
  Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat> ;Blood Cancer Journal. 2024 Mar 19
• Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?
  Mostafa Abdallah, Kaaren Reichard, Naseema Gangat, Ayalew Tefferi> ;Blood Cancer Journal. 2024 Mar 18
• Prognostic impact ofmutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases.
  Farrukh, F., Abdelmagid, M., Mangaonkar, A., Patnaik, M., Al-Kali, A., Elliott, M., Begna, K., Hook, C., Hogan, W., Pardanani, A., Litzow, M., Ketterling, R., Gangat, ...> ;Haematologica. 2024 Mar 7
• 1 citations
  New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.
  Naseema Gangat, Ayalew Tefferi> ;American Journal of Hematology. 2024 May 1
• Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
  Anmol Baranwal, Mark Gurney, Rami Basmaci, Bahga Katamesh, Rong He, David S Viswanatha, Patricia Greipp, James Foran, Talha Badar, Hemant Murthy, Cecilia Arana Yi, Jea...> ;Haematologica. 2024 Feb 1
• Incidental discovery of KIT-mutated mastocytoma in a colon polyp.
  Naseema Gangat, Ellen McPhail, Kaaren Reichard, Attilio Orazi, Animesh Pardanani, Ayalew Tefferi> ;American Journal of Hematology. 2024 May 1
• 3 citations
  One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
  Karrar, O., Ketterling, R., Gangat, N., Al-Kali, A., Begna, K., Elliott, M., Wolanskyj-Spinner, A., Pardanani, A., Hanson, C., Tefferi, A.> ;Blood Cancer Journal. 2024 Jan 18
• 3 citations
  Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
  Tefferi, A., Pardanani, A., Gangat, N.> ;American Journal of Hematology. 2024 Feb 1
• Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate.
  Kendi, A., Pritzl, S., Kusne, Y., Halfdanarson, T., Hobday, T., Sonbol, M., Mangaonkar, A., Gangat, N., Shah, M., Patnaik, M.> ;Leukemia Research. 2024 Jan 1
• 3 citations
  Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxi...
  Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek Mang...> ;American Journal of Hematology. 2024 Feb 1
• The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.
  Barbui, T., Carobbio, A., Thiele, J., Rumi, E., Rambaldi, A., Vannucchi, A., , Gangat, N., Tefferi, A.> ;Blood Cancer Journal. 2023 Dec 15
• 1 citations
  TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
  Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H Al Ali, Aref Al-Kali, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Pa...> ;British Journal of Haematology. 2024 Apr 1
• 12 citations
  Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive...
  Naseema Gangat, Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begn...> ;American Journal of Hematology. 2024 Feb 1
• 2 citations
  Emergence ofmutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine.
  Naseema Gangat, Naresh Bellam, Kaaren Reichard, Ayalew Tefferi> ;Haematologica. 2024 Apr 1
• 2 citations
  Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
  Ayalew Tefferi, Maymona Abdelmagid, Aref Al-Kali, Mrinal Patnaik, William J Hogan, Kebede Begna, Naseema Gangat, Attilio Orazi, Dong Chen, Kaaren K Reichard, Animesh P...> ;American Journal of Hematology. 2024 Jan 1
• 3 citations
  Mast cell cytomorphology and treatment outcome in mast cell leukemia.
  Ayalew Tefferi, Animesh Pardanani, Aref Al-Kali, Hassan Alkhateeb, Kristen McCullough, Mrinal Patnaik, William J Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera...> ;American Journal of Hematology. 2024 Jan 1
• U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
  Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, James M Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B Alkhateeb, David Viswanatha, Rong He, Mithu...> ;Blood Cancer Journal. 2023 Sep 21
• 2 citations
  TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
  Mark Gurney, Patricia T Greipp, Troy Gliem, Ryan Knudson, Aref Al-Kali, Naseema Gangat, Terra Lasho, Abhishek A Mangaonkar, Christy M Finke, Mrinal M Patnaik> ;Leukemia Research. 2023 Nov 1
• 5 citations
  Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
  Ahmad Nanaa, Rong He, James M Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J Hogan, Mark R Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B Alkhateeb> ;British Journal of Haematology. 2024 Jan 1
• Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transpl...
  Kebede H Begna, Nadine H Abdallah, Michelle Janania-Martinez, Abhishek A Mangaonkar, Aruna Rangan, Jennifer L Herrick, Naseema Gangat> ;Haematologica. 2024 Feb 1
• 4 citations
  Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
  Animesh Pardanani, Ayalew Tefferi, Aref Al-Kali, Mrinal Patnaik, William J Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M Palmer, Naseema Gangat, Att...> ;American Journal of Hematology. 2024 Jan 1
• Join now to see all

Journal Articles

• MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal  
  Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature
• Determinants of Long-Term Outcome in Type 1 Calreticulin-Mutated Myelofibrosis  
  Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature